Applied Biosystems/Amersham
This article was originally published in The Gray Sheet
Executive Summary
Court-mediated settlement concludes patent litigation between the parties with cross-licensing agreement, co-development arrangement for joint development of DNA analysis technologies. An April 2001 summary judgement found that Applied Biosystems sequencing chemistry used with the Prism 3700 DNA analyzer system did not infringe an Amersham patent (1"The Gray Sheet" April 16, 2001, p. 17). A jury trial was set to begin to resolve other infringement claims...
You may also be interested in...
Celera Proteomics Facility On-Line With Goal Of 1 Mil. Sequences Daily
Celera Genomics' newly constructed, 33,000 square foot proteomics facility in Rockville, Maryland will be able to sequence 1 mil. proteins daily in a search for new disease diagnostic markers once it is fully operational, the firm says.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.